文献速递类风湿关节炎

长期低剂量糖皮质激素治疗类风湿关节炎的安全性与疗效:系统评价与荟萃分析

Safety and efficacy associated with long-term low-dose glucocorticoids in rheumatoid arthritis: a systematic review and meta-analysis.
PubMed 文献 · Rheumatology (Oxford) · 2023-01-01

该系统评价与荟萃分析纳入6项双盲、安慰剂对照随机试验共1078例类风湿关节炎患者,比较低剂量糖皮质激素(泼尼松≤7.5mg/天)与安慰剂至少2年的安全性和疗效。结果显示不良事件风险未见增加(发生率比1.08;95%CI 0.86,1.34;P=0.52),但感染风险升高(风险比1.4;95%CI 1.19-1.65),疾病活动度、功能和Larsen评分有改善。

要点

  • 长期低剂量糖皮质激素未增加不良事件风险(发生率比1.08;95%CI 0.86,1.34;P=0.52),证据质量低。
  • 感染风险升高(风险比1.4;95%CI 1.19-1.65),证据质量中等。
  • 疾病活动度(DAS28 -0.23;95%CI -0.43至-0.03)、功能(HAQ -0.09;95%CI -0.18至0.00)和Larsen评分(-4.61;95%CI -7.52至-1.69)有改善。

核心结论

  • 长期低剂量糖皮质激素在类风湿关节炎中无危害的证据质量为极低至中等,但糖皮质激素使用者感染风险增加。
  • 考虑到疾病修饰作用有中等至高质量证据,长期低剂量糖皮质激素的获益-风险比可能合理。

研究设计与样本

  • 方案化系统评价与荟萃分析(PROSPERO注册号CRD42021252528),纳入双盲、安慰剂对照随机试验,比较低剂量糖皮质激素(泼尼松≤7.5mg/天)与安慰剂至少2年。
  • 共纳入6项试验,1078例参与者;采用随机效应荟萃分析,使用Cochrane RoB工具和GRADE评估偏倚风险与证据质量。

主要发现

  • 不良事件风险未见增加(发生率比1.08;95%CI 0.86,1.34;P=0.52),证据质量低。
  • 死亡、严重不良事件、因不良事件退出及特殊关注不良事件的风险与安慰剂无差异(证据质量极低至中等)。
  • 感染在糖皮质激素组发生更频繁(风险比1.4;95%CI 1.19-1.65;证据质量中等)。
  • 疾病活动度改善(DAS28:-0.23;95%CI -0.43至-0.03)、功能改善(HAQ:-0.09;95%CI -0.18至0.00)、Larsen评分改善(-4.61;95%CI -7.52至-1.69),证据质量中等至高等。
  • 其他疗效结局包括Sharp van der Heijde评分未见糖皮质激素获益证据。

关键数值与推荐

  • 主要结局为不良事件;低剂量糖皮质激素定义为泼尼松≤7.5mg/天,疗程至少2年。
  • 不良事件发生率比1.08(95%CI 0.86,1.34;P=0.52),证据质量低。
  • 感染风险比1.4(95%CI 1.19-1.65),证据质量中等。
  • DAS28变化-0.23(95%CI -0.43至-0.03),HAQ变化-0.09(95%CI -0.18至0.00),Larsen评分变化-4.61(95%CI -7.52至-1.69)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 不良事件结局的证据质量低。
  • 死亡、严重不良事件、因不良事件退出及特殊关注不良事件的证据质量极低至中等。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The aim of this study was to assess the safety and efficacy of long-term low-dose glucocorticoids (GCs) in RA. METHODS: A protocolised systematic review and meta-analysis (PROSPERO No. CRD42021252528) of double-blind, placebo-controlled randomised trials (RCTs) comparing a low dose of GCs (≤ 7.5mg/day prednisone) to placebo over at least 2 years was performed. The primary outcome investigated was adverse events (AEs). We performed random-effects meta-analyses and used the Cochrane RoB tool and GRADE to assess risk of bias and quality of evidence (QoE). RESULTS: Six trials with 1078 participants were included. There was no evidence of an increased risk of AEs (incidence rate ratio 1.08; 95% CI 0.86, 1.34; P = 0.52); however, the QoE was low. The risks of death, serious AEs, withdrawals due to AEs, and AEs of special interest did not differ from placebo (very low to moderate QoE). Infections occurred more frequently with GCs (risk ratio 1.4; 1.19-1.65; moderate QoE). Concerning benefit, we found moderate to high quality evidence of improvement in disease activity (DAS28: -0.23; -0.43 to -0.03), function (HAQ -0.09; -0.18 to 0.00), and Larsen scores (-4.61; -7.52 to -1.69). In other efficacy outcomes, including Sharp van der Heijde scores, there was no evidence of benefits with GCs. CONCLUSION: There is very low to moderate QoE for no harm with long-term low dose GCs in RA, except for an increased risk of infections in GC users. The benefit-risk ratio might be reasonable forusing low-dose long-term GCs considering the moderate to high quality evidence for disease-modifying properties.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Palmowski A, Nielsen SM, Boyadzhieva Z, et al. Safety and efficacy associated with long-term low-dose glucocorticoids in rheumatoid arthritis: a systematic review and meta-analysis. Rheumatology (Oxford). 2023. PMID: 36810945. doi:10.1093/rheumatology/kead088

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。